GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » EBIT
中文

Telo Genomics (Telo Genomics) EBIT : $-2.28 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics EBIT?

Telo Genomics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-0.62 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Telo Genomics's annualized ROC % for the quarter that ended in Dec. 2023 was -4,831.07%. Telo Genomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -6,298.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Telo Genomics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -28.80%.


Telo Genomics EBIT Historical Data

The historical data trend for Telo Genomics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics EBIT Chart

Telo Genomics Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.79 -0.90 -1.03 -1.65 -2.12

Telo Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.52 -0.64 -0.50 -0.62

Competitive Comparison of Telo Genomics's EBIT

For the Diagnostics & Research subindustry, Telo Genomics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telo Genomics's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Telo Genomics's EV-to-EBIT falls into.



Telo Genomics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics  (OTCPK:TDSGF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Telo Genomics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-2.488 * ( 1 - 0% )/( (0.056 + 0.047)/ 2 )
=-2.488/0.0515
=-4,831.07 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Telo Genomics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.488/( ( (0.044 + max(-0.031, 0)) + (0.035 + max(-0.089, 0)) )/ 2 )
=-2.488/( ( 0.044 + 0.035 )/ 2 )
=-2.488/0.0395
=-6,298.73 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.046 + 0 + 0.063) - (0.14 + 0 + 0)
=-0.031

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.052 + 0 + 0.074) - (0.215 + 0 + 0)
=-0.089

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Telo Genomics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-2.283/7.926
=-28.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telo Genomics EBIT Related Terms

Thank you for viewing the detailed overview of Telo Genomics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Telo Genomics (Telo Genomics) Business Description

Traded in Other Exchanges
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.